How We Pick Products

The full selection desk lives in our company and member area. What is public is the method: three steps, two coordinate systems, and every score carries its evidence.

How we pick products: three steps, none skipped

①
Complete the data

A product with incomplete records produces hollow conclusions. CAS, HS code, uses, upstream/downstream, plants, deal records — every gap is filled before the next step.

②
Analyse the case

Two coordinate systems score every product: is it worth doing (medical need, treatment landscape, competition, IP, technical barriers, cost), and when to start (patent-expiry window).

③
Let the algorithm pick

Scores roll up into two lists: products to co-develop with plants (fill capability gaps) and products to push (with sales ammo behind them). Anything under-served by data stays on the fill-first list — the algorithm never promotes it.

Two coordinate systems

The qualitative frame follows Dr. Cheng Juan's product-analysis approach (six dimensions); the timing frame comes from our own patent-cliff timeline. Every score carries its evidence.

Worth doing? · six dimensions

Medical need
Success rates × daily cost — how big is the pool
Treatment landscape
Could a new therapy displace it
Competition
Named makers × countries — who is already in
IP
Four patent routes — can they be designed around
Technical barriers
Registration / tech / production / investment gates
Manufacturing cost
Sourcing, capacity, break-even

When to start · patent-cliff timing

Expiredtiming 10
Expiring in 1–2 yrstiming 9
Expiring in 3–5 yrstiming 7
Expiring in 6–8 yrstiming 4
Beyond 8 yrstiming 2

Why these picks — not a black box

Regional demand

Markets differ: India buys intermediates, the EU/US buys APIs and finished forms. Regional epidemiology and registration paths shape each recommendation.

Therapeutic focus

Products are matched by therapeutic area — endocrine, anti-infective, oncology, CNS… area first, molecule second.

Patent timing

Core-patent expiry is the starting gun. Expired and near-expiry products come first — with the caveat that polymorph/process/formulation patents and extensions are excluded, and we say so.

What a scorecard looks like (example)

Example — shows the scorecard layout only; not data for any real product.

Data completeness
72 / 100
Missing: HS code, deal records
Six-dimension score
6.8 / 10
3 dimensions pending evidence — provisional
Timing
Expiring in 1–2 yrs
Core patent expires 2027 (public sources)
Pick tier
Fill data first
No promotion until the picture is complete

In the real board, every score expands to show its evidence. A score without provenance never makes the table — that is a hard rule in our internal selection desk.

Public toolbox

The full selection desk — candidate pool, score rankings, plant-partnership and go-push lists — lives inside our company and member area. It is an operations tool, not a public one. Talk to our BD team for our read on any specific product.